Wednesday, September 26, 2007

GlobeImmune Garners $41.2M

Louisville, Colorado-based GlobeImmune said today that it has raised $41.2M in a Series C financing round, led by Wexford Capital. Other new investors in the firm included GlobeImmune included Celgene, Inc., Mellon Family Investment Company, Richard King Mellon Foundation, Eminent Venture Capital, Boston Life Science Venture, and WRF Capital. Also participating were its existing investors, which include HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, Lilly Ventures, Medica Venture Partners, Adams Street Partners, Biogen Idec, Inc., Pac-Link Bioventures, China Investment and Development (CIDC), Yasuda Enterprise Development, Partners Healthcare, and GC&H Investments. The venture round brings the company's total raised to $88M. GlobeImmune is developing therapeutics for treating infection diseases. The firm's hepatitis C treatment is entering Phase 2 clinical trials. Its treatment for pancreas cancer is also in Phase 2 trials. More information »